简介：Dr. Chen-Hua Liu will present the results of a randomized trial assessing response-guided therapy using pegylated-interferon plus ribavirin in HCV genotype 2 patients. He and his colleagues analyzed data from several experimental groups， concluding that weight-based dosing did not substantially effect SVR at 16 weeks in those patients who achieve RVR， in those who did not have an RVR， a 48 week therapy did improve SVR.